PDCD1 and ovarian neoplasm: We found that treating ovarian tumor-bearing mice with a combination of anti-PD-1/IGF1R led to a more potent response, as reflected by higher rates of up-regulated and down-regulated gene expression, compared to separate treatments (Figure 7B).